WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration
SEOUL, South Korea, March 3, 2021 /PRNewswire/ Wellmarker Bio(www.wmbio.co) announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.
Under the approval, Wellmarker Bio will seek to recruit a total of 100 advanced cancer patients in multiple centers, including sites in Australia such as the Linear Clinical Center and Monash Hospital, to conduct clinical trials in two stages: Phase Ia (dose escalation) and Phase Ib (dose expansion). We plan to study the drug s safety at various doses in Phase Ia, and in Phase Ib, we will conduct studies for indication expansion as well as combination therapy with chemotherapy, other targeted or cancer immunotherapy drugs along with validation of our pre
In March and April 2020, mental health claim lines for individuals aged 13-18, as a percentage of all medical claim lines, approximately doubled over the same months in the previous year.
Share
Source: AP Photo/Yuki Iwamura
A Los Angeles-based nursing home is accused of dumping residents on the streets or in unqualified resident facilities in order to take on COVID-positive patients.
The skilled nursing home facility, which has 99 beds in total, is accused of intentionally neglecting residents while pushing others out to make room for COVID-positive patients because Medicare provided higher reimbursement payments, The Los Angeles Times reported.
According to Los Angeles City Attorney Mike Feuer, a settlement was reached with Lakeview Terrance, the nursing home in question. The facility is required to pay $130,000 in civil penalties and $40,000 in costs and fees the city attorney s office incurred.
Apervita, Diameter Health join forces to improve data quality for value-based care contracting
Health IT company Apervita will leverage Diameter Health s capabilities which include cleaning and enriching clinical data to enhance data quality for stakeholders looking to create value-based care contracts.
Shares1
A new health IT partnership aims to improve clinical data quality and thereby increase the volume of data available for care quality measurement.
The partnership will combine Chicago-based Apervita and Farmington, Connecticut-based Diameter Health’s expertise to provide payers, providers and other healthcare stakeholders with access to clean clinical data for value-based care delivery, said Rick Howard, Apervita’s chief product officer, in an email.
The Hyderabad-based vaccine maker said whole virion inactivated Covid-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The